Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
McKesson
Medtronic
Deloitte
Julphar
Cerilliant
Fish and Richardson
Federal Trade Commission

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021302

« Back to Dashboard

NDA 021302 describes ELIDEL, which is a drug marketed by Valeant Bermuda and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the ELIDEL profile page.

The generic ingredient in ELIDEL is pimecrolimus. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pimecrolimus profile page.
Summary for 021302
Tradename:ELIDEL
Applicant:Valeant Bermuda
Ingredient:pimecrolimus
Patents:1
Therapeutic Class:Dermatological Agents
Pharmacology for NDA: 021302
Mechanism of ActionCalcineurin Inhibitors
Suppliers and Packaging for NDA: 021302
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELIDEL pimecrolimus CREAM;TOPICAL 021302 NDA Valeant Pharmaceuticals North America LLC 0187-5100 N 0187-5100-01
ELIDEL pimecrolimus CREAM;TOPICAL 021302 NDA Valeant Pharmaceuticals North America LLC 0187-5101 N 0187-5101-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CREAM;TOPICALStrength1%
Approval Date:Dec 13, 2001TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 26, 2018Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021302

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Bermuda ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Bermuda ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
US Army
Deloitte
McKesson
Accenture
Citi
Fish and Richardson
Cantor Fitzgerald
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.